Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00758524 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 628
- Enrollment target
NCT00758524 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 628 participants.
The verdict
NCT00758524, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 628 participants
- Enrollment target
Study Summary
This study was a proof-of-efficacy, dose finding study of LCI699 in participants with mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure (BP) lowering effect, safety and tolerability of LCI699 as compared to placebo and eplerenone.
Interventions
- DRUG LCI699
- DRUG Eplerenone
- DRUG LCI699-matching Placebo
- DRUG Eplerenone-matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 628 participants |
| Start Date | 2008-09-11 |
| Est. Completion | 2009-07-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00758524
The ClinicalTrials.gov registry entry for NCT00758524 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 628 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which LCI699 is the first listed.
NCT00758524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00758524 about?
NCT00758524 is a clinical study titled "A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension". This study was a proof-of-efficacy, dose finding study of LCI699 in participants with mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure (BP) lowering effect, safety and tolerability of LCI699 as compared to placebo and eplerenone.
What is the current status of trial NCT00758524?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 628 participants. The study started on 2008-09-11. Estimated completion is 2009-07-02.
What interventions are being tested in trial NCT00758524?
The interventions under investigation include: LCI699 (DRUG), Eplerenone (DRUG), LCI699-matching Placebo (DRUG), Eplerenone-matching Placebo (DRUG).
Who is sponsoring clinical trial NCT00758524?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.